倩碧控股(08367.HK)斥6,000萬元收購內地自動售藥機公司
倩碧控股(08367.HK)公布,於昨日(4日)與賣家陶樺瑋訂立協議,以代價6,000萬元收購目標公司Lucky State Investment全部已發行股本。
目標公司主要透過附屬從事售藥機銷售及相關服務,包括獲授權負責內地製藥集團的「二十四小時未來藥房藥機項目」,在中國推廣及銷售自動售藥機,為期10年。
代價將於完成後以發行承兌票據的方式支付,承兌票據期限為三年,年利率為5%,利息按月支付。
公司表示,一直在積極尋找新的商機,以實現業務多元化,相信疫情導致門診服務暫停,住院人數下降,進一步推動處方藥銷售向醫院外轉移。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.